An Australasian, Multi-centre, Randomized, Double-blind, Placebo-controlled Trial Of The Efficacy Of Fluoxetine In Improving Functional Recovery After Acute Stroke
Funder
National Health and Medical Research Council
Funding Amount
$2,306,367.00
Summary
Stroke is one of the top three causes of disability. Treatments that improve recovery after stroke are lacking. We reviewed the world literature and found a number of very small studies which, together, suggest that the antidepressant drug, fluoxetine, may improve the recovery in stroke patients. AFFINITY is a large trial in 1600 Australians and New Zealanders with stroke which aims to find out whether taking fluoxetine for 6 months after a stroke improves recovery compared to a placebo.
I am a practising hospital neurologist and world leader in the prevention and treatment of stroke. Our research aims to realise exciting new break-throughs for stroke sufferers by testing the effectiveness and safety of new treatments that promise to improve recovery of function of damaged brain and reduce disability after stroke, and to prevent recurrent strokes.
The critical role of kisspeptin/neurokinin/dynorphin (KNDy) neurons in gonadotropin releasing hormone (GnRH) release. The brain controls fertility through the secretion of its primary stimulatory factor, gonadotropin releasing hormone (GnRH). Brain cells producing three key peptide hormones, kisspeptin, neurokin B and dynorphin (termed KNDy cells) are vital for the control of GnRH. This project will detail the role of KNDy cells in puberty and reproduction.